Gilead Wagers $275m On Pionyr’s Myeloid Tuners
Executive Summary
Deal snapshot: Pionyr’s top two candidates are preclinical, but Gilead buys near 50% stake in the hope that myeloid tuners will work in combination with anti-PD-L1 agents in solid tumors.